PDCD1 and head and neck squamous cell carcinoma: Published in 2019, a separate study in a HNSCC patient responding to anti-PD-1 antibody (pembrolizumab) impressively identified T cells specific to a novel in-frame DEK–AFF2 gene fusion [117], suggesting that T cells specific to fusion genes contributed the positive outcome in this patient.